A Phase I, Multi-center, Open-label, Single-arm, Dose-escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activities of FCN-411 Monotherapy in Advanced Non-small Cell Lung Cancer

Trial Profile

A Phase I, Multi-center, Open-label, Single-arm, Dose-escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activities of FCN-411 Monotherapy in Advanced Non-small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs FCN-411 (Primary)
  • Indications Non-small cell lung cancer
  • Focus First in man; Pharmacokinetics
  • Sponsors Ahon Pharmaceutical
  • Most Recent Events

    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top